Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on ...
With respect to ANAVEX 3-71, also in October, Anavex announced encouraging preliminary electroencephalo EEG biomarker results from Part A of the ongoing placebo-controlled Phase II clinical study of ...
The drug was added to their standard treatment and, after four weeks, significantly more patients with the EEG biomarker achieved clinical response compared to those without that profile.
NeuroVigil, with its 72 patents, broke valuation records to leverage your brain state without surgery. Two billion people worldwide are affected by a nervous system disorder, incl ...
Thus, identifying a non-invasive, scalable marker of E/I could provide valuable insights into the neural mechanisms of chronic pain and aid in developing clinically useful biomarkers. Recently, the ...
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing ...
Company to host a webcasttoday at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback